Fresh From the Bench: Latest Federal Circuit Court Cases
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., Appeal No. 2018-1638, -1639, -1640, -1641, -1642, -1643 (Fed. Cir. July 20, 2018)
In a groundbreaking decision issued on Friday, the Federal Circuit held that tribal sovereignty immunity cannot be asserted in inter partes review (IPR). The ruling stems from an IPR of patents related to treatment for alleviating the symptoms of chronic dry eye.
Allergan Inc. owned patents relating to Restasis, a treatment of chronic dry eye (“the Restasis Patents”). Allergan sued generic drug manufacturers Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Akorn, Inc. (“Appellees”), alleging infringement of the Restasis Patents. The generic drug manufacturers subsequently petitioned for IPRs of the Restasis Patents. While the IPRs were pending, Allergan transferred title of the Restasis Patents to the Saint Regis Mohawk Tribe. The Mohawk Tribe moved to terminate the IPRs—asserting tribal immunity—and Allergan moved to withdraw from the IPR proceedings.
On appeal, the Federal Circuit considered whether tribal sovereign immunity can be used to shield patents from IPRs. The panel looked to the Supreme Court’s decision in Fed. Maritime Comm’n v. S.C. State Ports Auth., 535 U.S. 743 (2002) (“FMC”), which reviewed the scope of state sovereign immunity in light of government agency-initiated proceedings. The FMC decision turned on whether commission adjudications “are the type of proceedings from which the Framers would have thought the States possessed immunity when they agreed to enter the Union.” The Supreme Court distinguished two categories: (1) private party-initiated proceedings similar to civil litigation, which warrant sovereign immunity application; (2) traditional agency action, which does not.
ALSO THIS WEEK
Interval Licensing LLC v. AOL, Inc., Appeal No. 2016-2502, -2505, -2506, -2507 (Fed. Cir. July 20, 2018)
In an appeal from judgment that a patent’s claims were directed to ineligible subject matter under 35 U.S.C. S 101, the Federal Circuit affirmed. The patent in suit covered computer software with an “attention manager” as part of its GUI. In a 22-page decision that follows the history of the abstractness doctrine and then applies the Supreme Court’s two-part test in Alice Corp. Pty. v. CLS Bank Int’l, 134 S. Ct. 2347 (2014), the Court found the claims to be abstract. Of note to the reader is the 17-page opinion by Judge Plager concurring in the result. But in a scathing indictment of the entire “abstractness” doctrine, Judge Plager “dissent[ed] from [the Federal Circuit’s] continued application of this incoherent body of doctrine.” Judge Plager’s opinion is well worth the read.
Opinion can be found here.
Blackbird Tech LLC v. ELB Electronics, Inc., Appeal No. 2017-1703 (Fed. Cir. July 16, 2018)
In an appeal from a district court judgment of noninfringement the Federal Circuit vacated and remanded, finding that the district court erred in construing the term “attachment surface” in a patent directed to a lighting fixture. The Court found that the district court improperly imported a limitation from an embodiment in the specification, which limitation was also originally present in the claim and expressly eliminated during prosecution “to resolve [35 U.S.C. §] 112 issues.” The Court rejected defendants’ argument that the prosecution history was ambiguous because the “112 issues” were not explained, finding that any skilled artisan would understand it to be an amendment required for patentability. Judge Reyna dissented, arguing that the limitation was required to give meaning to the limiting preamble.
Opinion can be found here.
Written by: Scott D. Eads and Nika F. Aldrich, Schwabe, Williamson & Wyatt
Contributors: Jason A. Wrubleski, Angela E. Addae
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…